Health Care · Services-Medical Laboratories · Nasdaq · CIK 1439725 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $25.54 · Day +14.32% · Mkt cap $236M · 1Y +213.8% · Off 52W high −3.3% · Vol (1Y) 113.2% Price2023-08-21 → 2026-08-19 BDSX close: $33.2 on 2023-08-21 to $25.5 on 2026-08-19. Split-adj closes · 240 of 1,375 · price returnⓘ At a glance | Short interest1.5% of sh out | | Days to cover2.7d | | 13F net flow (QoQ)+3.95% | | Top-10 13F concentration83.5% | | Next report (est.)2026-11-01 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$102.9M | | Earnings (TTM)-$27.8M | | Net margin−39.8% | | Sales growth 3Y32.3% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+275.6% | | 1Y+213.8% | | 3Y−23.1% | | 5Y−84.0% | | Since incept. (ann.)−40.9% |
Total return · from 2021-02-22ⓘ Risk | Ann. volatility (1Y)113.2% | | Ann. volatility (3Y)99.7% | | Sharpe (1Y)1.52 | | Sharpe (3Y)0.42 | | Max drawdown (1Y)−49.3% | | Max drawdown (3Y)−89.7% | | Beta (3Y vs SPY)−0.24 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| AIGH Capital Management LLC | 758,328 | $11M | 7.69% | new | | Telemark Asset Management, LLC | 489,824 | $7M | 4.97% | +49.4% | | Aberdeen Group plc | 458,438 | $7M | 4.65% | +74.7% | | Soleus Capital Management, L.P. | 416,599 | $6M | 4.23% | new | | Birchview Capital, LP | 286,804 | $4M | 2.91% | +0.0% | | VANGUARD CAPITAL MANAGEMENT LLC | 255,161 | $4M | 2.59% | new | | Opaleye Management Inc. | 238,047 | $3M | 2.41% | new | | MARSHALL WACE, LLP | 141,636 | $2M | 1.44% | new |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-05 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-05 | −$0.71 | — | $26.9M | +34.2% | | 2026-03-31 | 2026-05-04 | −$0.81 | — | $25.6M | +42.3% | | 2025-12-31 | 2026-02-26 | — | — | $28.8M | +40.8% | | 2025-09-30 | 2025-11-03 | −$1.16 | — | $21.8M | +19.9% |
As-reported XBRL · next 2026-11-01 est.ⓘ Segment mixFY2025 (ended Dec 2025) Diagnostic Tests 89% · Development Services 11% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
